The Covid Test Device Approval (CTDA) was introduced during the pandemic as a measure to regulate an influx of new Covid-19 tests. Its retention post-Covid means any test on the UK market which tests for Covid – even as part of testing for other infections – still needs to pass an additional regulatory step unique to UK. This has kept products off the UK market and is costly and time-consuming.

On Friday 4th July, BIVDA hosted a webinar examining what the newly-released NHS 10-Year Plan means for the future of diagnostics, reaching an audience of 114 from our membership, the NHS and government.

A year after coming to power, the Government have released their plan for NHS reform.

London, United Kingdom, April 1st, 2025 – The British In Vitro Diagnostics Association (BIVDA), along with leading industry and health charities, today launched a new policy declaration that highlights the value of community diagnostics and their role in a future neighbourhood NHS.

BIVDA is excited to announce a new partnership with MedBoard, an innovative cloud platform that centralises global medical, MedTech, Digital Health, and Pharma information. MedBoard empowers professionals, teams, and organisations with accessible, cutting-edge digital tools to enhance their work and decision-making.

BIVDA welcomed members to our event to network and hear from a stellar line-up of speakers from industry and government.We were delighted to host a successful and well-attended Parliamentary Reception last week in the Churchill Room in the House of Commons.We would like to extend a special thank you to former Health Minister, Baroness Thornton for stepping in to host the event at the last minute after Lord Darzi had to travel abroad. Her informed commentary and analysis after each presentation e...

17 October 2024, London, UK – A new group of MPs and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget.The call comes from the newly-formed All-Party Parliamentary Group (APPG) for Life Sciences, which held its first meeting in Parliament on Tuesday to discuss what the Labour government must do to ensure the UK remains a powerhouse for life sciences research and commercialisatio...

BHR Biosynex is pleased to have worked with the Company Chemists’ Association (CCA) to produce a report that demonstrates how a community pharmacy diabetes screening service would save the NHS £50m in recurring costs each year.The report ‘Increasing Access to Diabetes Screening and Prevention Through Community Pharmacy’ highlights the need to create a clear national patient pathway for diabetes detection and prevention and used BHR Biosynex’s MoREM® service as a...

The Infection Management Coalition (IMC), of which BIVDA is a member, welcomes the publication of the Independent Investigation of the NHS in England, conducted by Lord Ara Darzi. Its findings highlight the persistent challenges in infection prevention and control (IPC), antimicrobial resistance (AMR) and uptake and investment in diagnostics. Progress in all three areas has been slow and urgent action is needed to reduce the devastating impact of infection on people, the NHS and the UK economy.

The diagnostic industry is ready to support the NHS to resolve the issues identified in the Darzi Review. The Review makes stark reading; the Prime Minister assesses it as “reform or die”. Poor policy, austerity, and the pandemic have crippled the NHS. Systemic and structural pressures throughout the NHS have normalised appalling service.